Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1521-3757|126|37|9999-10003

ISSN： 0044-8249

Source： ANGEWANDTE CHEMIE, Vol.126, Iss.37, 2014-09, pp. : 9999-10003

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

By  

ANGEWANDTE CHEMIE INTERNATIONAL EDITION, Vol. 53, Iss. 37, 2014-09 ,pp. : 9841-9845

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date

By  

MEDICINAL RESEARCH REVIEWS, Vol. 35, Iss. 3, 2015-05 ,pp. : 586-618

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multifunctional Antibody Agonists Targeting Glucagon‐like Peptide‐1, Glucagon, and Glucose‐Dependent Insulinotropic Polypeptide Receptors

By  

ANGEWANDTE CHEMIE, Vol. 128, Iss. 40, 2016-09 ,pp. : 12663-12666

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

By  

CHEMMEDCHEM, Vol. 13, Iss. 1, 2018-01 ,pp. : 30-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers

By  

ANGEWANDTE CHEMIE INTERNATIONAL EDITION, Vol. 54, Iss. 24, 2015-06 ,pp. : 7022-7027

John Wiley & Sons Inc

Access to resources Recommend Favorite